BCG Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The bCG vaccine market size in 2026 is estimated at USD 189.47 million, growing from 2025 value of USD 178.44 million with 2031 projections showing USD 255.76 million, growing at 6.18% CAGR over 2026-2031. This report is Segmented by Age Group (Paediatric, Adults), Application (Tuberculosis, Bladder Cancer), Distribution Channel (Public, Private), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global BCG Vaccine Market Trends and Insights

Rising prevalence of drug-resistant & latent tuberculosis

Drug-resistant strains now influence national vaccination strategies, prompting intensified BCG coverage across South-East Asia where 45% of global tuberculosis cases were recorded in 2023. Indonesia’s leadership in Phase 3 trials for the M72/AS01E candidate underscores how endemic regions fund next-generation solutions while upholding current BCG schedules. Clinical evidence shows 45.4% efficacy for adolescent revaccination, supporting programs aimed at preventing latent infection progression. High-burden geographies therefore represent the largest addressable pool for incremental doses as health agencies integrate revaccination policies. This driver will affect demand for the BCG vaccine market through the decade because multidrug resistance remains a persistent epidemiological threat.

Expanding universal newborn immunization mandates

Policy makers increasingly view BCG as part of holistic infant health strategies; Finland’s 2026 procurement plan confirms adoption even in low-incidence settings. WHO guidelines recommend BCG for HIV-exposed infants and family contacts, adding scale to national rollouts. Indonesia’s National Immunization Strategy recorded 80% coverage in 2024 despite pandemic-related disruptions, showing how middle-income economies turn mandates into executable programs. Infrastructure upgrades funded by Asia-Pacific governments now include cold chain expansion, ensuring dose stability from factory to clinic. Medium-term growth momentum in the BCG vaccine market will therefore track the rollout cadence of these newly legislated schedules.

Adverse events & contraindications in immunocompromised recipients

WHO classifies known HIV infection as a formal contraindication to BCG because disseminated disease reaches mortality rates nearing 75% in affected infants. Protocols now delay vaccination for neonates born to tuberculosis-positive mothers until preventive therapy is completed, complicating workflow in resource-limited facilities. Oman’s surveillance data revealed 9.2 BCG-linked adverse events per 100,000 doses, primarily abscesses, prompting calls for stronger pre-screening. These safety concerns reduce coverage in precisely the regions with the highest tuberculosis burden, narrowing the addressable pool for the BCG vaccine market. Medium-term headwinds persist while clinician education and improved diagnostics scale across endemic zones.

Other drivers and restraints analyzed in the detailed report include:

• Government-funded stockpiling & catch-up campaigns
• Growing adoption of BCG as adjunct immunotherapy for non-muscle-invasive bladder cancer
• Supply shortages linked to limited global producers

Segment Analysis

Pediatric immunization continued to dominate in 2025, accounting for 81.92% of total doses distributed and anchoring public-health funding decisions. Newborn vaccination coverage regularly tops 90% in 154 countries, underscoring how early-life protection shapes the BCG vaccine market. Bladder cancer treatment is driving faster expansion on the adult side, where 6.95% CAGR is forecast through 2031 as oncologists adopt combination regimens validated by recent approvals. Adult demand is further reinforced by growing interest in booster strategies for trained immunity, with multiple university trials evaluating respiratory infection outcomes among older populations. Over the forecast horizon, pediatric volumes will maintain scale advantages, yet the adult segment offers higher marginal revenue per vial because oncology doses command premium pricing in hospital settings. Hospitals therefore form dedicated procurement units that lock in multi-year contracts, boosting visibility for suppliers planning capacity upgrades. Although pediatric subsidy mechanisms keep prices in check, rising production costs are likely to flow more easily into adult oncology list prices, providing margin upside for manufacturers.

The adult opportunity also benefits from payer willingness to reimburse immunotherapies that delay radical cystectomy, lowering overall treatment costs for healthcare systems. Regulatory agencies now encourage adaptive licensing pathways that expedite access for BCG-unresponsive indications, setting precedents that could be replicated for new recombinant strains. Together these dynamics illustrate how the BCG vaccine market balances volume stability in pediatrics with value growth in adults, creating a diversified revenue stream resilient to single-segment shocks.

Complete Report Scope:

• By Age Group
  • Paediatric
  • Adults
• By Application
  • Tuberculosis
  • Bladder Cancer
• By Distribution Channel
  • Public
  • Private
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Asia-Pacific maintained leadership with 37.52% of global revenue in 2025, and its 7.12% CAGR outlook through 2031 outpaces every other region. High tuberculosis incidence, rising healthcare expenditure, and robust manufacturing ecosystems in India and China collectively sustain the largest regional slice of the BCG vaccine market. Indonesia’s participation in M72/AS01E Phase 3 trials highlights simultaneous investment in next-generation solutions while national immunization programs continue distributing classical BCG formulations. China’s vaccine output meets domestic needs and supports exports via bilateral aid channels, further anchoring Asia-Pacific supply dominance.

North America and Europe form the second-tier cluster, delivering steady demand anchored in oncology use and policy frameworks that reward innovation. The United States is addressing chronic shortages by supporting Merck’s multi-hundred-million-dollar facility in North Carolina, expected to triple domestic capacity upon completion in 2030. Europe benefits from coordinated procurement under joint tender programs that negotiate favorable pricing while promoting supply diversification; the UK’s rapid approval of Anktiva exemplifies regulatory momentum favoring BCG-based combination regimens.

Middle East & Africa and South America collectively exhibit untapped potential as tuberculosis elimination initiatives gain traction alongside improvements in cold-chain logistics. WHO’s TB-Free Central Asia initiative emboldens Central Asian republics to accelerate vaccination throughput, while South Africa’s past shortage-driven morbidity spikes have prompted the treasury to ring-fence funding for emergency buffer stocks. Brazil’s integration of tuberculosis screening into prenatal care signals an emerging maternal-child health paradigm that amplifies BCG coverage in public hospitals. These developments suggest that the BCG vaccine market will experience progressively balanced geographical contributions, replacing the historic reliance on a handful of Asian buyers.

List of Companies Covered in this Report:

• Serum Institute of India
• Japan BCG Laboratory
• AJ Biologics
• Merck
• Statens Serum Institut
• GreenSignal Bio Pharma Pvt. Ltd.
• Biomed Lublin
• Taj Pharmaceuticals Ltd.
• NPO Microgen
• China National Biotec Group (CNBG)
• BCG Vaccine Laboratory (India)
• Bio Farma (Persero)
• Intervax Ltd.
• Sanofi S.A. (Sanofi Pasteur)
• Indian Immunologicals
• PT BioFarma Indonesia
• Chiron Behring Vaccines Pvt. Ltd.
• Cipla Ltd. (BCG on-co-pack)
• Valneva
• Microbix Biosystems Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support